PSNLEarnings•businesswire•
Personalis Reports Second Quarter 2025 Financial Results
Sentiment:Positive (70)
Summary
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal®
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 5, 2025 by businesswire